Condition

Primary Membranous Nephropathy clinical trials and research

• 16Clinical trials
• 1NIH research projects
• 26Countries

Newest Primary Membranous Nephropathy clinical trials

All recruiting trials (16)

• Surovatamig for adults with anti‑PLA2R primary membranous nephropathy

  This study will test whether subcutaneous surovatamig is safe and can reduce heavy proteinuria in adults with anti‑PLA2R–positive primary membranous nephropathy.

  Recruiting Phase 2 AstraZeneca · Los Angeles, California and 26 other locations · NCT07571746

• SHR-2173 injections for adults with primary membranous nephropathy

  This Phase II test will try SHR-2173 injections in adults (18–75) with biopsy-proven primary membranous nephropathy to see if they are safe, reduce disease activity, and to measure how the drug acts in the body.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Nanjing, Jiangsu · NCT07289763

• Povetacicept for people with primary membranous nephropathy

  This trial tests whether povetacicept is safe and helps people with primary membranous nephropathy, with tacrolimus listed as an intervention in the protocol.

  Recruiting at 116 sites Phase 2/3 Vertex Pharmaceuticals Incorporated · Montgomery, Alabama and 116 other locations · NCT07204275

• ALXN1920 for adults with primary membranous nephropathy

  This trial will test whether ALXN1920 reduces urine protein in adults with primary membranous nephropathy who are at high risk of progression compared with placebo.

  Recruiting at 35 sites Phase 2 Alexion Pharmaceuticals, Inc. · Loma Linda, California and 39 other locations · NCT07157787

• Budoprutug for primary membranous nephropathy (Phase 2)

  This trial will test whether budoprutug, an anti-CD19 antibody given by IV, is safe and tolerated and may reduce proteinuria in adults with PLA2R-positive primary membranous nephropathy who still have high protein in their urine despite RAAS blockers.

  Recruiting at 35 sites Phase 2 Climb Bio, Inc. · Denver, Colorado and 37 other locations · NCT07096843

• Evaluating YK012 for treating primary membranous nephropathy

  This study is testing a new treatment called YK012 to see if it can help people with primary membranous nephropathy feel better and how safe it is to use.

  Recruiting Phase 1 Excyte Biopharma Ltd · Beijing, Beijing Municipality · NCT06982729

• Felzartamab infusions for adults with primary membranous nephropathy

  This study tests whether felzartamab infusions help adults with primary membranous nephropathy reach complete remission of proteinuria compared with tacrolimus.

  Recruiting at 116 sites Phase 3 Biogen · Huntsville, Alabama and 116 other locations · NCT06962800

• Observing the effects of rituximab in treating primary membranous nephropathy

  This study is testing whether adding hormones to rituximab can help people with primary membranous nephropathy feel better compared to using rituximab alone.

  Recruiting First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT06893328

• Comparing obinutuzumab to cyclophosphamide and glucocorticoids for treating primary membranous nephropathy

  This study is testing if a new drug called obinutuzumab works just as well as the standard treatment of cyclophosphamide and glucocorticoids for people with primary membranous nephropathy.

  Recruiting Phase 3 Huashan Hospital · Shanghai, Shanghai Municipality · NCT06781944

• Finerenone for primary membranous nephropathy: efficacy and safety

  This trial tests whether adding finerenone to standard ACEI/ARB treatment lowers urine protein over six months in adults with primary membranous nephropathy.

  Recruiting Phase 4 First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT06573411

• Using CAR NK cells to treat adults with lupus nephritis

  This study is testing a new CAR NK cell therapy to see if it can safely help adults with active lupus nephritis feel better.

  Recruiting at 18 sites Phase 1/2 Nkarta, Inc. · Little Rock, Arkansas and 18 other locations · NCT06557265

• Treatment of Primary Membranous Nephropathy with B007

  This study is testing a new treatment called B007, along with cyclosporin, to see if it can improve kidney function and reduce protein levels in people with primary membranous nephropathy.

  Recruiting at 21 sites Phase 2/3 Shanghai Jiaolian Drug Research and Development Co., Ltd · Beijing and 20 other locations · NCT06470191

• Evaluating WAL0921 for kidney diseases

  This study is testing a new drug called WAL0921 to see if it can help people with different types of kidney diseases feel better.

  Recruiting at 25 sites Phase 2 Walden Biosciences · Los Angeles, California and 49 other locations · NCT06466135

• Treatment of Primary Membranous Nephropathy with SNP-ACTH Gel

  This study is testing a new gel treatment for primary membranous nephropathy to see if it works better than an existing medication called rituximab.

  Recruiting at 31 sites Phase 3 Cerium Pharmaceuticals, Inc. · Los Angeles, California and 30 other locations · NCT05696613

• Treatment of Primary Membranous Nephropathy with a New Monoclonal Antibody

  This study is testing a new injectable antibody treatment for people with primary membranous nephropathy to see if it is safe and how well it works.

  Recruiting at 6 sites Phase 1 Shanghai Jiaolian Drug Research and Development Co., Ltd · Zhengzhou, He'nan and 5 other locations · NCT05668403

• Treatment of Primary Membranous Nephropathy with Rituximab and Corticosteroids

  This study is testing whether combining rituximab with corticosteroids works better than just rituximab alone for treating primary membranous nephropathy in people who haven't been treated before.

  Recruiting Phase 4 First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT05514015

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how autoantibodies affect kidney function in membranous nephropathy

  This study is looking at how certain antibodies in the body affect kidney health in people with primary membranous nephropathy, with the hope of finding better ways to treat the disease and help patients feel better.

  NIH research Boston Medical Center · Boston, United States · NIH-10667599

Related topics

Quick answers

How many Primary Membranous Nephropathy clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in China (13 trials), United States (8 trials), Australia (5 trials), Brazil (4 trials), United Kingdom (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 3: 3, Phase 2/3: 2, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →